CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

59.99

24-January-25 15:45:00

15 minutes delayed

Stocks

-2.30

-3.69%

Today's range

59.35 - 62.29

ISIN

N/A

Source

NASDAQ

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

26 Jul 2024 09:16:01 By NetDania Notify
NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

25 Jul 2024 10:29:14 By NetDania Notify
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

22 Jul 2024 15:05:00 By Nasdaq GlobeNewswire
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

24 Jun 2024 15:15:00 By Nasdaq GlobeNewswire
NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

06 Jun 2024 08:45:18 By NetDania Notify
NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

05 Jun 2024 12:50:40 By NetDania Notify
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

28 May 2024 07:00:00 By Nasdaq GlobeNewswire
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

01 May 2024 15:05:00 By Nasdaq GlobeNewswire
Corcept Completes Enrollment in Phase 4 CATALYST Trial

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

24 Apr 2024 15:05:00 By Nasdaq GlobeNewswire
NetDania - New 12 months Low: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

22 Apr 2024 08:59:41 By NetDania Notify
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

15 Feb 2024 15:07:00 By Nasdaq GlobeNewswire
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

15 Feb 2024 15:02:00 By Nasdaq GlobeNewswire
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

08 Feb 2024 15:05:00 By Nasdaq GlobeNewswire
Corcept Appoints Roberto Vieira as President, Oncology

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.